# Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

> **NCT01151423** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 75 (actual)

## Conditions studied

- Acquired Thrombotic Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Caplacizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01151423
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151423, "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01151423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*